114 related articles for article (PubMed ID: 8831190)
1. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
Yamane N; Chilima BZ; Tosaka M; Okazawa Y; Tanno K
Kekkaku; 1996 Aug; 71(8):453-8. PubMed ID: 8831190
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Kawahara S; Tada A; Nagare H
Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
[TBL] [Abstract][Full Text] [Related]
3. [Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 May; 68(5):367-70. PubMed ID: 8331881
[TBL] [Abstract][Full Text] [Related]
4. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J
Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
[TBL] [Abstract][Full Text] [Related]
5. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
6. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
7. Determination of the susceptibility in vitro of 54 isolates of Mycobacterium fortuitum against three fluoroquinolones using two methods.
Hernández AM; Arias A; Felipe A; Alvarez R; Sierra A
J Chemother; 1995 Apr; 7(2):109-13. PubMed ID: 7666115
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic potential of sparfloxacin for preventing mycobacterial infections].
Kawahara S; Tada A; Takeuchi M; Kamisaka K; Okada C; Mishima Y; Soda R; Takahashi K; Kibata M; Nagare H
Kekkaku; 1994 May; 69(5):351-6. PubMed ID: 8007520
[TBL] [Abstract][Full Text] [Related]
9. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
Rastogi N; Goh KS
Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872
[TBL] [Abstract][Full Text] [Related]
11. [In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis].
Fukuyama M; Kawakami K; Suda O; Imagawa Y
Kansenshogaku Zasshi; 1995 Sep; 69(9):987-90. PubMed ID: 7594800
[TBL] [Abstract][Full Text] [Related]
12. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
Tomioka H; Saito H; Sato K
Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Karak K; De PK
Indian J Med Res; 1995 Apr; 101():147-9. PubMed ID: 7751043
[TBL] [Abstract][Full Text] [Related]
15. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
[TBL] [Abstract][Full Text] [Related]
16. [In vitro antimycobacterial activity of a new quinolone, T-3761].
Tomioka H; Sato K; Saito H
Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
[TBL] [Abstract][Full Text] [Related]
17. [In vitro antimycobacterial activities of a new quinolone, balofloxacin].
Kawahara S; Tada A; Nagare H
Kekkaku; 2001 Jan; 76(1):29-31. PubMed ID: 11211780
[TBL] [Abstract][Full Text] [Related]
18. Minimal inhibitory concentrations of lomefloxacin and minocycline against drug-sensitive and drug-resistant isolates of M. tuberculosis compared on L-J and 7H11 media.
Kamala T; Herbert D; Venkatesan P; Paramasivan CN
Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):375-8. PubMed ID: 9401493
[TBL] [Abstract][Full Text] [Related]
19. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
[TBL] [Abstract][Full Text] [Related]
20. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Bhusal Y; Shiohira CM; Yamane N
Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
